Celgene Corp (NASDAQ:CELG) Stock Sentiment Falls to 0.83

May 17, 2018 - By Richard Doty

Celgene Corporation (NASDAQ:CELG) Corporate Logo

Positions for Celgene Corp (NASDAQ:CELG)

“Big money sentiment for Celgene Corp (NASDAQ:CELG) in Q4 2017 decreased to 0.83, according to Securities and Exchange Commission filings. So its down -0.34, from 2017Q3’s 1.17. 529 investment professionals started new or increased holdings, while 634 cut down and sold holdings in Celgene Corp so the sentiment is negative. These funds own 561.38 million shares, that’s down from 603.99 million shares in 2017Q3. Funds holding Celgene Corp in top 10 changed to 38 from 119 for a decrease of 81. In total 156 funds closed positions, 478 reduced and 411 increased. Also 118 funds bought new Celgene Corp stakes.

Most Celgene Corp Shareholders

Birchview Capital Lp owns 744,051 shares in Celgene Corp as of Q4 2017. As of Q4 2017, 2.11 million shares of Celgene Corp are owned by Oaktop Capital Management Ii L.P.. Selkirk Management Llc reported 260,000 shares. The Switzerland-based fund Bb Biotech Ag have invested about 10.06% of the active investment manager’s stock portfolio in Celgene Corp. The United Kingdom-based fund Edinburgh Partners Ltd looks positive on Celgene Corp, possessing 315,906 shares.

Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide.The firm is valued at $59.09 billion. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes , and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis, psoriasis, and ankylosing spondylitis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.The P/E ratio is 22.35. The companyÂ’s products also include VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and acute myeloid leukemia (AML); THALOMID to treat patients with multiple myeloma and erythema nodosum leprosum; and RITALIN and FOCALIN XR products.

The stock decreased 0.76% or $0.62 during the last trading session, reaching $81.36.Celgene Corporation has volume of 6.04 million shares. Since May 17, 2017 CELG has declined 31.28% and is downtrending. CELG underperformed by 42.83% the S&P 500.

Earnings report for Celgene Corporation (NASDAQ:CELG) is anticipated on July, 26., according to RTT. Analysts forecast $1.87 EPS, which is $0.19 up or 11.31 % from 2017’s $1.68 EPS. If $1.87 is reported, CELG’s profit will be $1.36B for 10.88 P/E. After $1.61 EPS was reported previous quarter, analysts now see EPS growth of 16.15 % for Celgene Corporation.

First Pacific Advisors Ltd Limited Liability Company has 4,175 shs for 0% of their capital. Orbis Inv (Us) Ltd Liability Corporation reported 1.72% in Celgene Corporation (NASDAQ:CELG). Yorktown Mngmt And Research holds 0.06% or 2,100 shs in its capital. Inverness Counsel Ltd Com Ny holds 1.13% of its capital in Celgene Corporation (NASDAQ:CELG) for 172,860 shs. Bridges Inv Counsel has invested 1.36% in Celgene Corporation (NASDAQ:CELG). Regent Inv Mgmt, Kentucky-based fund reported 50,063 shs. Texas Permanent School Fund owns 214,931 shs for 0.28% of their capital. Asset Management has invested 0.25% of its capital in Celgene Corporation (NASDAQ:CELG). 4,350 were accumulated by Salem Invest Counselors. The New York-based Allen Management Limited Liability Com has invested 0.02% in Celgene Corporation (NASDAQ:CELG). Wendell David Associates Incorporated reported 93,025 shs. Gateway Advisory Ltd holds 0.4% in Celgene Corporation (NASDAQ:CELG) or 13,720 shs. Conning holds 0.07% or 20,324 shs. Amundi Pioneer Asset Mgmt owns 814,675 shs or 0.13% of their US capital. Livforsakringsbolaget Skandia Omsesidigt accumulated 57,910 shs.

Celgene Corporation had 3 sales and 1 insider buy since February 8, 2018. This’s net activity of $3.58 million. On Thursday, February 8 $299,594 worth of Celgene Corporation (NASDAQ:CELG) was bought by Alles Mark J. On Friday, February 23 $1.26M worth of stock was sold by MARIO ERNEST. Another trade for 18,500 shs valued at $1.77M was sold by KAPLAN GILLA.

Celgene Corporation (NASDAQ:CELG) Ratings Coverage

In total 20 analysts cover Celgene (NASDAQ:CELG). “Buy” rating has 13, “Sell” are 0, while 7 are “Hold”. (NASDAQ:CELG) has 65% bullish analysts. With $152.0 highest and $90 lowest PT, Celgene has $122 average PT or 49.95% above the current ($81.36) price. 35 are the (NASDAQ:CELG)’s ratings reports on 17 May 2018 according to StockzIntelligence Inc. On Wednesday, February 28 Stifel Nicolaus maintained Celgene Corporation (NASDAQ:CELG) with “Buy” rating. On Wednesday, February 28 the rating was maintained by Credit Suisse with “Outperform”. On Wednesday, April 4 RBC Capital Markets maintained Celgene Corporation (NASDAQ:CELG) with “Buy” rating. The company rating was maintained by Piper Jaffray on Thursday, December 21. On Friday, January 5 Bank of America downgraded Celgene Corporation (NASDAQ:CELG) to “Hold” rating. The company rating was maintained by Guggenheim on Thursday, January 25. On Tuesday, February 13 the firm has “Buy” rating given by Barclays Capital. On Friday, April 13 the stock of Celgene Corporation (NASDAQ:CELG) has “Equal-Weight” rating given by Morgan Stanley. On Thursday, January 18 the firm earned “Hold” rating by Piper Jaffray. The company rating was maintained by Morgan Stanley on Monday, May 7.

For more Celgene Corporation (NASDAQ:CELG) news posted recently go to: Seekingalpha.com, Seekingalpha.com, Fool.com, Seekingalpha.com or Streetinsider.com. The titles are as follows: “Celgene’s (CELG) Management Presents at Bank of America Merrill Lynch Healthcare Conference (Transcript)” posted on May 16, 2018, “Celgene And Otezla Are Cracking” on May 14, 2018, “Celgene Starts the Year With a Bang” with a publish date: May 14, 2018, “My 2 Cents On The Ozanimod Saga” and the last “Celgene (CELG) to Present New Clinical Data in Blood Cancer and Solid Tumor Therapies at ASCO” with publication date: May 16, 2018.

Celgene Corporation (NASDAQ:CELG) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: